Heart failure & cardiomyopathiesSecondary analysis
Effects of Empagliflozin on Collagen Biomarkers in Patients with Heart Failure: Findings from the EMPEROR Trials
- Secondary analysis of the EMPEROR-Preserved and EMPEROR-Reduced randomised trials
Authors' conclusion
Our observations are consistent with experimental observations that empagliflozin down-regulates profibrotic signalling.
Study context
- Population
- Patients with heart failure (HF) enrolled in the EMPEROR-Preserved and EMPEROR-Reduced trials
- Participants
- 1,084 patients
- Comparison
- Empagliflozin vs placebo
- Empagliflozinn = 545
- Placebon = 539reference
Primary result
As reported in the abstract
PICP
- week 12; 5% reduction
- geometric mean ratio 0.95 (95% CI 0.91–0.99); P = 0.012
- week 52; 8% reduction
- geometric mean ratio 0.92 (95% CI 0.88–0.97); P = 0.003
Further findings
| Outcome | geometric mean ratio (95% CI) | P value |
|---|---|---|
| PRO-C3 — Empagliflozin vs Placebo · week 12 | 0.98 (0.95–1.02) | P = 0.42 |
| PRO-C3 — Empagliflozin vs Placebo · week 52; 7% reduction | 0.93 (0.89–0.98) | P = 0.003 |
PINP, PRO-C6, C1M, C3M
- No impact of empagliflozin on other collagen markers
Baseline biomarkers and outcomes
- Higher PICP associated with primary endpoint (HF hospitalization or CV death)
- PRO-C6 and PINP associated with sustained worsening of kidney function
- PRO-C3, C1M, C3M not associated with HF severity or study outcomes
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effects of Empagliflozin on Collagen Biomarkers in Patients with Heart Failure: Findings from the EMPEROR Trials. Eur J Heart Fail. Published 28 December 2023. doi:10.1002/ejhf.3101
Summarised from the published abstract; every number is checked against it